tbuckley/cabot-search huggingface dataset:
Medical Needs in the Gold Coast
Authors: I. Fraser
Journal: BMJ (1954)

nuclear substance.Healing is by fibrous tissue formation, and a satisfactory result is a firm fibrous ankylosis of the damaged joint.Favourable conditions for such healing can only be established by avoidance of mechanical strains on and movement of the lumbar spine.In other words, rest and immobilization of this region are the corner stones of conservative treatment, and it is difficult to see how any other measures could speed up, or even affect other than adversely, natural healing.For obvious reasons the figures compiled by insurance companies are not necessarily the most reliable guides to true disability periods, nor is there any rea4 reason why a Metropolitan policeman should not carry out his duties wearing a lumbar corset with incorpor- ated Goldthwait steels.-Iam, etc.,
Full-thickness septotomy of Zenker’s diverticulum
Authors: Iman Andalib, Daniel Kats, Michel Kahaleh
Journal: Endoscopy (2019)

A 92-year-old woman with a past medical history of moderate-to-severe mitral regurgitation, chronic obstructive pulmonary disease, and Zenker’s diverticulum presented with chronic dysphagia and weight loss. Her condition warranted a minimally invasive intervention. Thus, the decision was made to perform an endoscopic septotomy to treat the Zenker’s diverticulum. This procedure has been described for decades and has been proven to be efficacious [1] [2] [3]. We describe a full-thickness resection of this procedure.
Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Authors: Nitin Jain, Michael J. Keating, Philip A. Thompson, Jan A. Burger, Alessandra Ferrajoli, Zeev E. Estrov, Gautam M. Borthakur, Koichi Takahashi, Prithviraj Bose, Nathan H. Fowler, Tapan M. Kadia, Naval G. Daver, Marina Y Konopleva, Yesid Alvarado, Musa Yilmaz, Courtney D. DiNardo, Maro Ohanian, Naveen Pemmaraju, Elias Jabbour, Koji Sasaki, Rashmi Kanagal-Shamanna, Keyur Patel, Jeffrey L. Jorgensen, Sa A Wang, Naveen Garg, Xuemei Wang, Katrina Sondermann, Nichole Cruz, Chongjuan Wei, Ana Ayala, William Plunkett, Hagop M. Kantarjian, Varsha Gandhi, William G. Wierda
Journal: Blood (2019)
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents
Authors: Shibadas Biswal, Humberto Reynales, Xavier Saez-Llorens, Pio Lopez, Charissa Borja-Tabora, Pope Kosalaraksa, Chukiat Sirivichayakul, Veerachai Watanaveeradej, Luis Rivera, Felix Espinoza, LakKumar Fernando, Reynaldo Dietze, Kleber Luz, Rivaldo Venâncio da Cunha, José Jimeno, Eduardo López-Medina, Astrid Borkowski, Manja Brose, Martina Rauscher, Inge LeFevre, Svetlana Bizjajeva, Lulu Bravo, Derek Wallace
Journal: New England Journal of Medicine (2019)

Dengue, a mosquito-borne viral disease, was designated a World Health Organization top 10 threat to global health in 2019.We present primary efficacy data from part 1 of an ongoing phase 3 randomized trial of a tetravalent dengue vaccine candidate (TAK-003) in regions of Asia and Latin America in which the disease is endemic. Healthy children and adolescents 4 to 16 years of age were randomly assigned in a 2:1 ratio (stratified according to age category and region) to receive two doses of vaccine or placebo 3 months apart. Participants presenting with febrile illness were tested for virologically confirmed dengue by serotype-specific reverse-transcriptase polymerase chain reaction. The primary end point was overall vaccine efficacy in preventing virologically confirmed dengue caused by any dengue virus serotype.Of the 20,071 participants who were given at least one dose of vaccine or placebo (safety population), 19,021 (94.8%) received both injections and were included in the per-protocol analysis. The overall vaccine efficacy in the safety population was 80.9% (95% confidence interval [CI], 75.2 to 85.3; 78 cases per 13,380 [0.5 per 100 person-years] in the vaccine group vs. 199 cases per 6687 [2.5 per 100 person-years] in the placebo group). In the per-protocol analyses, vaccine efficacy was 80.2% (95% CI, 73.3 to 85.3; 61 cases of virologically confirmed dengue in the vaccine group vs. 149 cases in the placebo group), with 95.4% efficacy against dengue leading to hospitalization (95% CI, 88.4 to 98.2; 5 hospitalizations in the vaccine group vs. 53 hospitalizations in the placebo group). Planned exploratory analyses involving the 27.7% of the per-protocol population that was seronegative at baseline showed vaccine efficacy of 74.9% (95% CI, 57.0 to 85.4; 20 cases of virologically confirmed dengue in the vaccine group vs. 39 cases in the placebo group). Efficacy trends varied according to serotype. The incidence of serious adverse events was similar in the vaccine group and placebo group (3.1% and 3.8%, respectively).TAK-003 was efficacious against symptomatic dengue in countries in which the disease is endemic. (Funded by Takeda Vaccines; TIDES ClinicalTrials.gov number, NCT02747927.).
Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A Single Center Retrospective Analysis
Authors: Manu Pandey, Mahesh Swaminathan, Elizabeth A. Griffiths, James E. Thompson, Amanda Przespolewski, Swapna Thota, Jeffrey Baron, Tara L. Cronin, Eunice S. Wang
Journal: Blood (2019)
Combination of Venetoclax and Hypomethylating Agents in Myeloid Malignancies in Patients Unfit for Intensive Chemotherapy - Real World Data from a Tertiary Care Centre in India. Is It Time to Bid Adieu to 3+7?
Authors: Sumeet Prakash Mirgh, Jyotsna Kapoor, Shinto Francis Thekuddan, Vishvdeep Khushoo, Faran Naim, Ambar Garg, Narendra Agrawal, Rayaz Ahmed, Dinesh Bhurani
Journal: Blood (2019)
CBMT-40. THE RELATIONSHIP BETWEEN GLIOMA AND THE GUT-BRAIN AXIS
Authors: Anthony Patrizz, Soheil Zorofchain, Gabriella Hines, Takeshi Takayasu, Yoshihiro Otani, Jessica Swanner, Pedram Honarpisheh, Nitin Tandon, Vasanta Putluri, Nagireddy Putluri, Bhanu Priya Ganesh, Balveen Kaur, Louise McCullough, Leomar Y Ballester, Yoshua Esquenazi
Journal: Neuro-Oncology (2019)

Abstract Recent studies demonstrate the potential role of the microbiome in immune-oncology, revealing specific microbial taxa can augment the effects of various therapeutic modalities against tumors. Gut dysbiosis, a disequilibrium in the host’s bacterial ecosystem, can potentially lead to overrepresentation of some bacteria and favor chronic inflammation and immunosuppression. However, the effects of microbial dysbiosis on non-gastrointestinal cancers in particular gliomas are unknown. Here, we explored the effects of glioma and Temozolomide (TMZ) on the fecal microbiome (FM) in mice (n=24) and FM and metabolome in humans (n=40). Aged C57/B6 mice were implanted with Gl261 tumor cells or vehicle and were assigned to one of the following treatment (oral) groups: vehicle, 5mg/kg TMZ or 25mg/kg TMZ beginning 14 days after surgery for 3-weeks following a 5 day on/2 day off treatment. Fecal samples were collected prior to surgery, at treatment initiation and weekly thereafter until sacrifice and sequenced for 16s RNA. Fecal samples were collected from humans with newly diagnosed glioma before resection, chemoradiation, and after chemoradiation (16s RNA, metabolomic, neurotransmitter analysis). In mice, FM beta diversity was significantly altered with glioma (p=0.003) while the alpha diversity remained unchanged. At a genus and family level analysis the relative abundance of Bacteroides (p=0.01) and Bacteroidaceae (p=0.02) was increased. Beta diversity of mice receiving 5mg/kg TMZ changed from baseline (p=0.02). Collectively, this suggests that glioma alters the FM, to what consequence remains to be explored. Alpha (Observed OTUs, p=0.029) and beta diversity (p=0.034) differences in mice correlated with survival (&lt; 25 - &gt;25 days). In humans, norepinephrine and 5-hydroxyindoleacetic acid were significantly lower in glioma patients at diagnosis compared to controls. Our findings demonstrate for the first time the relationship between glioma and the gut-brain axis. Understanding alterations in the FM in glioma patients may allow novel interventions and should be further investigated.
EXTH-41. A NANOPARTICLE-BASED CANCER-SELECTIVE GENE TRANSFER STRATEGY FOR LOCALIZED THERAPY OF MALIGNANT HIGH GRADE GLIOMAS
Authors: Divya Rao, Ashish Phal, Varun Naga, Karina Negron, Yumin Oh, Justin Hanes, Jung Soo Suk
Journal: Neuro-Oncology (2019)

Abstract Treatment for malignant high grade gliomas entails surgery, followed by chemotherapy and/or radiation. Despite the intensive care, there is a ~90% recurrence rate. This is attributed to suboptimal efficacy of treatments in tackling widespread cancer cells. We have previously developed nanoparticles that provide widespread therapeutic distribution both in healthy and tumor tissues, but are incapable of differentiating between them. This limitation applies to the current standard-of-care and state-of-the-art gene therapies. Here, we evaluate the efficacy of DNA nanoparticles carrying promoters that drive transgene expression specifically in tumor cells to achieve widespread yet cancer-selective gene transfer in high grade gliomas. To identify tumor-specific promoters, we used ELISA to confirm elevated expression of proteins previously reported to be upregulated in tumor tissue. We observed that expression of survivin in cancer cells was significantly greater than that of other cancer-rich proteins, exhibiting two orders of magnitude greater levels in rodent and human cancer cells compared to their respective healthy cells. Furthermore, the CMV promoter mediated similarly high expression in healthy cells, whereas the level achieved by the survivin promoter was significantly lower, if not negligible, suggesting its tumor specificity. Likewise, CMV-driven plasmids delivered into the brain by the nanoparticles mediated virtually identical volumetric distribution of transgene expression in both normal and tumor tissues in vivo. In contrast, nanoparticles carrying survivin-driven plasmids provided widespread transgene expression only in an orthotopically established tumor, but not healthy brain tissue. Additionally, we demonstrate therapeutic efficacy in an established brain tumor model using the DNA nanoparticles carrying survivin promoter-driven plasmids expressing a therapeutic protein. We identified survivin promoter as a lead TSP and confirmed its ability to mediate highly efficient and widespread but cancer-selective transgene expression with the aid of our nanoparticles uniquely designed to penetrate in healthy and tumor tissues.
Preclinical Evaluation of CD8+ Anti-Bcma mRNA CAR T-Cells for the Control of Human Multiple Myeloma
Authors: Liang Lin, Lijie Xing, Shih-Feng Cho, Kenneth Wen, Phillip A Hsieh, Metin Kurtoglu, Yi Zhang, C Andrew Stewart, Kenneth C. Anderson, Yu-Tzu Tai
Journal: Blood (2019)
PrEP Drug Is Approved for Some Patients but Not for Others
Authors: Rebecca Voelker
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis
Authors: Paola Guglielmelli, Alessandra Carobbio, Elisa Rumi, Valerio De Stefano, Lara Mannelli, Francesco Mannelli, Giada Rotunno, Giacomo Coltro, Silvia Betti, Chiara Cavalloni, Maria Chiara Finazzi, Juergen Thiele, Mario Cazzola, Alessandro M. Vannucchi, Tiziano Barbui
Journal: Blood (2019)
CMET-29. DETECTING TUMOR MUTATIONS IN CEREBROSPINAL FLUID: LIQUID BIOPSY FOR THE DIAGNOSIS OF CENTRAL NERVOUS SYSTEM METASTASES
Authors: Mauli Shah, Soheil Zorofchian, Chieh Lan, Dzifa Duose, Peter Hu, Jay-Jiguang Zhu, Rajyalakshmi Luthra, Yoshua Esquenazi, Leomar Y Ballester
Journal: Neuro-Oncology (2019)

Abstract There is a critical need for better methodologies to diagnose and monitor patients with central nervous system (CNS) tumors. Recent advancements in the use of circulating tumor DNA (ctDNA) show that it is a promising tool for the evaluation of patients with primary or metastatic CNS tumors. Cerebrospinal fluid (CSF) is a more suitable sample type to evaluate metastatic CNS cancers than plasma. The current techniques for diagnosing metastatic CNS tumors include imaging (e.g., MRI), examination of tumor cells in CSF (CSF-cytology) and biopsies. However, MRI and CSF-cytology have poor specificity and sensitivity, respectively, and brain biopsies are invasive. The objective of this study is to optimize and validate a next generation sequencing (NGS) assay to detect ctDNA in the CSF of patients with metastatic CNS tumors. We have compared several methods to isolate ctDNA from CSF and identified the optimal method based on the quantity and quality of ctDNA obtained. CSF-ctDNA was extracted using QIAamp Circulating Nucleic Acid kit from CSF patient samples (CNS tumor= 10, Breast cancer=17, Lung cancer=8, Ovarian cancer=1, Melanoma=1, B-cell lymphoma=2, and Uterine cancer=1). We analyzed CSF-ctDNA mutations with the OncomineTM Pan-Cancer cell-free assay and found mutations in 19/40 (47.5%) CSF samples. The targeted panel detected 22 single nucleotide variations involving 11 genes and TP53 was the most commonly mutated gene. Copy number variations were detected in FGFR3, MYC, CCND1, CCND3, FGFR1, and CDK4 genes. We compared the sensitivity of the NGS assay to detect ctDNA with CSF-cytology and found that 7/22 (31.8%) CSF-cytology negative patients were positive for CSF-ctDNA. In conclusion, CSF-ctDNA targeted sequencing is more sensitive than CSF-cytology in the evaluation of patients with CNS metastasis. This approach will improve the diagnosis and management of primary and metastatic CNS tumors.
NCMP-15. BEVACIZUMAB FOR THE TREATMENT OF CEREBRAL RADIATION NECROSIS: A RETROSPECTIVE COHORT STUDY
Authors: A Luitse, Jan Dankbaar, Filip De Vos, Susanne Fonville, Pierre Robe, Tatjana Seute, Joost Verhoeff, Tom Snijders
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Cerebral radiation necrosis (RN) is a critical complication of radiotherapy for brain tumors. Treatment with corticosteroids provides suboptimal symptom relief, and may have considerable side effects. Small-scale studies support the use of bevacizumab, but systematic data from clinical practice on its efficacy and toxicity remain scarce. METHODS In this retrospective cohort study, we included consecutive patients with symptomatic RN that underwent treatment with bevacizumab in our academic neuro-oncology clinic. RN was diagnosed based on imaging, histology or both. The primary outcomes were reported neurological improvement during follow-up, the duration of response, the reported improvement on MRI, and radiological outcome according to RANO criteria. Other outcomes included reduction of dexamethasone dose and the occurrence of adverse events. RESULTS Of the 37 included patients (39 RN-episodes), the majority had a glioblastoma (n = 22) or other diffuse glioma (8), followed by brain metastases (4) or other (3). Clinical response was reported in 17 RN-episodes (43.6%) and lasted for a median of 13 weeks (IQR 6–32 weeks). Radiological improvement during follow-up was reported in 29 RN-episodes (80.6%). RANO-defined radiological responses included 1 complete response (3.4%), 7 partial responses (24.1%), 1 minor response (3.4%) and 17 stable disease (58.6%). In total, 36 adverse events occurred, most commonly venous thrombo-embolism, hypertension and dyspnea, with 8 grade III-IV complications and 2 deaths (grade V) which were possibly related to bevacizumab. Of 32 patients on dexamethasone, 9 (28.1%) had completely stopped its use at treatment cessation. CONCLUSION This observational study confirms that patients with cerebral RN can benefit both clinically and radiologically from bevacizumab treatment in a real-life clinical setting, although our results are more modest than previous literature suggests. The high prevalence of – sometimes severe – adverse events should be weighed against the possible clinical benefit when counselling patients about this treatment option.
Hepcidin, Soluble Transferrin Receptor, and Other Biomarkers of Iron Status Distributions in Healthy 2 Years Old Infants from a National Ambulatory Study in France
Authors: Anne-Sylvia Sacri, Thibaud Lefebvre, Mariane De Montalembert, Alain Bocquet, Piotr Gembara, Brigitte Pinçant, Serge Hercberg, Corinne Levy, Amandine Ganon, Laurent Gouya, Martin Chalumeau
Journal: Blood (2019)
Intermittent Transfusion Independence Is Associated with Improved Overall Survival in Patients with Transfusion Dependent MDS
Authors: Rena Buckstein, Lisa Chodirker, Michelle Geddes, Nancy Zhu, Grace Christou, Mitchell Sabloff, Mary-Margaret Keating, Brian Leber, Heather A. Leitch, Karen W.L. Yee, Eve St-Hilaire, Nicholas Finn, Thomas J. Nevill, John Storring, April Shamy, Versha Banerji, Mohamed Elemary, Robert Delage, Alexandre Mamedov, Liying Zhang, Aksharh Kirubananthaan, Richard A. Wells
Journal: Blood (2019)
30 years of sublingual immunotherapy
Authors: Giovanni Passalacqua, Diego Bagnasco, Giorgio Walter Canonica
Journal: Allergy (2019)

Allergen Immunotherapy (AIT) was introduced in clinical practice on an empirical basis more than 100 years ago. Since the first attempts, AIT was administered subcutaneously. Indeed, other routes of administration were proposed and studied, in particular to improve the safety, but only the sublingual route (SLIT) achieved a credibility based on evidence and was then accepted as a viable "alternative" option to the subcutaneous route. SLIT was largely used in clinical trials and clinical practice in this last 30 years. Thus, a large amount of data is available, coming from either controlled trials and postmarketing surveillance studies. It is clear that SLIT is overall effective, but it is also clear that the efficacy is not "class-related," as derived from meta-analyses, but restricted to each specific product. The 30-year lasting use of SLIT allowed to clarify many clinical aspects, such as efficacy, safety, use in asthma, regimens of administration, and optimal doses. In parallel, the mechanisms of action of AIT were elucidated, and new indications were proposed (eg food allergy, atopic dermatitis). In addition, the introduction of molecular-based diagnosis, allowed to better refine the prescription of SLIT, based on specific sensitization profiles. The present article will describe the origin and evolution of SLIT for respiratory allergy, taking into account the clinical context that suggested this form of treatment, the recently developed aspects, the future perspectives and unmet needs, This is not, therefore, a systematic review, rather a narrative historical description of the past history, and a look forward to the future opportunities.
Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children’s Oncology Group Studies P9904 and P9905
Authors: Naomi Winick, Paul L. Martin, Meenakshi Devidas, Jonathan Shuster, Michael J. Borowitz, W. Paul Bowman, Eric Larsen, Jeanette Pullen, Andrew Carroll, Cheryl Willman, Stephen P. Hunger, William L. Carroll, Bruce M. Camitta
Journal: Leukemia (2019)
NIMG-47. VOLUMETRIC ANALYSIS OF PHASE 2 AND 3 TRIALS IN RECURRENT GLIOBLASTOMA TREATED WITH VB-111 WITH OR WITHOUT BEVACIZUMAB OR BEVACIZUMAB MONOTHERAPY
Authors: Benjamin Ellingson, Catalina Raymond, Jingwen Yao, Jodi Goldman, Jacob Schlossman, Caleb Tran, Andrew Brenner, Nicholas Butowski, Patrick Wen, Tamar Rachmilewitz Minei, Yael Cohen, Dror Harats, Timothy Cloughesy
Journal: Neuro-Oncology (2019)

Abstract VB-111 is a non-replicating adenovirus carrying a pro-apoptotic transgene for TNFR1/Fas under the control of a modified murine promoter to pre-proendothelin 1. The transgene is expressed only in angiogenic endothelial cells, and therefore VB-111 results in targeted apoptosis of neovascular vessels. The current study characterizes the quantitative radiographic results and impact on OS in phase 2 and 3 trials of recurrent glioblastoma (GBM) patients treated with VB-111 with or without bevacizumab (BV) or BV monotherapy. MRI data from a phase 2 (NCT01260506) and randomized, double arm, controlled phase 3 (GLOBE; NCT02511405) trial of VB-111 in recurrent GBM were used in current study: Arm A) VB-111 monotherapy until progression followed by combination VB-111 and bevacizumab (BV) (“Primed Combination”; Phase 2; N=24); Arm B) VB-111 in combination with BV (“Unprimed Combination”; Phase 3; N=124); Arm C) BV monotherapy (“Control”; Phase 3; N=120). Contrast enhanced T1-weighted digital subtraction was used to quantify tumor volume at all time points. Baseline tumor volume was prognostic for OS in all treatment groups when controlling for therapy and age (Cox, P&lt; 0.001, HR=1.02). In patients with smaller tumors (&lt; 25mL), the “primed combination” cohort (Arm A) from the phase 2 trial had a significant OS advantage compared to both upfront combination of VB-111 and BV (Arm B; P=0.0094, HR=0.53; median OS = 7 vs. 15mo) as well as BV alone (Arm C; P=0.025, HR=0.58; median OS=8.5 vs. 15mo). Patients with a radiographic response (&gt;65% reduction) had a significant survival difference from non-responders when controlling for age, baseline tumor volume, and treatment arm (P=0.0014, HR=0.58). Responders to VB-111 monotherapy or combination therapy after priming with VB-111 exhibited characteristic, expansive areas of necrosis in areas of initial disease.
A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma
Authors: Tanaya Shree, Michael S. Khodadoust, Debra K. Czerwinski, Matthew J. Frank, Wan X. Hong, Rachel Greenstein, Steven R. Long, Brock Martin, Ronald Levy
Journal: Blood (2019)
Central Nervous System (CNS) Infiltration Assessment Using Cerebrospinal Fluid Flow Cytometry in Hematologic Malignancies: A Single Center Retrospective Analysis of Clinical Outcomes
Authors: Eduardo Cerello Chapchap, Carolina Feres, Laiz Cameirão Bento, Daniela Schimidell, Rodolfo Patussi Correia, Anderson Marega Alexandre, Sonia Tsukasa Nosawa, Eduardo de Carvalho Pedro, Andressa da Costa Vaz, Rodrigo De Souza Barroso, Carlos Augusto Senne Duarte, Nydia Strachman Bacal, Nelson Hamerschlak
Journal: Blood (2019)
Quality of Life Impairment in Adult Patients with ACUTE Lymphoblastic Leukemia with Minimal Residual Disease in France
Authors: Stephane Lepretre, Chantal Touboul, Alain Flinois, Lucie Kutikova, Kahina Makhloufi, Jean-Vannak Chauny, Gaëlle Désaméricq
Journal: Blood (2019)
Genome Wide Transcriptomic Analysis Identifies Dysregulated Splicing Factor Profile with Molecular and Functional Role in Multiple Myeloma
Authors: Anil Aktas Samur, Mehmet Kemal Samur, Michael A Lopez, Sanika Derebail, Kenneth C. Anderson, Herve Avet-Loiseau, Giovanni Parmigiani, Mariateresa Fulciniti, Nikhil C. Munshi
Journal: Blood (2019)